Emergent BioSolutions (EBS) Misses Q2 EPS by $1.21
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.23 +6.13%
EPS Growth %: -138.7%
Financial Fact:
Provision for (benefit from) income taxes: 13.17M
Today's EPS Names:
ANAB, ANIX, MNY, More
EPS Growth %: -138.7%
Financial Fact:
Provision for (benefit from) income taxes: 13.17M
Today's EPS Names:
ANAB, ANIX, MNY, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of $0.33, $1.21 worse than the analyst estimate of $1.54. Revenue for the quarter came in at $397.5 million versus the consensus estimate of $398.93 million.
GUIDANCE:
Emergent BioSolutions sees Q3 2021 revenue of $1700-1900 billion, versus the consensus of $1.8 billion.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rent the Runway (RENT) Reports Q2 Loss of $0.38/sh
- Adobe Systems (ADBE) Tops Q3 EPS by 6c, Offers Guidance
- Chewy (CHWY) Reports In-Line Q2 EPS, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
